Salvage chemotherapy regimens with arsenic trioxide for relapsed or refractory neuroblastoma: a promising approach.
Humans
Arsenic Trioxide
/ administration & dosage
Neuroblastoma
/ drug therapy
Salvage Therapy
Female
Male
Child, Preschool
Child
Neoplasm Recurrence, Local
/ drug therapy
Retrospective Studies
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Topotecan
/ administration & dosage
Infant
Treatment Outcome
Adolescent
Drug Resistance, Neoplasm
Cyclophosphamide
/ therapeutic use
Arsenic trioxide
Neuroblastoma
Refractory
Relapsed
Salvage chemotherapy
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
12 Sep 2024
12 Sep 2024
Historique:
received:
26
06
2024
accepted:
02
09
2024
medline:
13
9
2024
pubmed:
13
9
2024
entrez:
12
9
2024
Statut:
epublish
Résumé
In patients with relapsed or refractory neuroblastoma (NB), the limited efficacy of conventional chemotherapies necessitates the exploration of new treatment options. Previous studies have highlighted the anti-tumor properties of arsenic trioxide (ATO) in high-risk NB (HR-NB). This study aims to assess the effectiveness and safety of ATO combined with salvage chemotherapy regimens, featuring cyclophosphamide and topotecan, as a foundational treatment for children with relapsed or refractory NB. Eleven patients (four relapsed, seven refractory NB) were retrospectively analyzed for efficacy and treatment relevance. Salvage treatments, incorporating ATO (0.18 mg/kg daily for 8 h intravenously on days 1 to 10), were administered upon disease progression or relapse, with assessments conducted every two cycles. Treatments had 63.6% efficacy, with six cases of partial response, one case of stable disease, and four cases of disease progression. The overall response rate was 54.5%, and the disease control rate was 63.6%. Importantly, the systemic toxicity experienced by patients following salvage chemotherapy with ATO was mild. Salvage chemotherapy regimens featuring ATO demonstrated potential for prolonging disease stabilization for relapsed or refractory HR-NB patients, exhibiting both favorable efficacy and safety profiles. This suggests further clinical exploration and promotion of this therapeutic approach in the treatment of NB. Point 1. The inadequate effectiveness of traditional chemotherapy in individuals with recurrent or resistant neuroblastoma (NB) necessitates the investigation of novel therapeutic approaches. Point 2. Arsenic trioxide (ATO)-based salvage treatments are both effective and less toxic in relapsed or refractory NB. Point 3. Salvage chemotherapy regimens incorporating ATO have shown promise in extending disease stabilization in relapsed or refractory high-risk NB patients, with favorable efficacy and safety profiles, which suggests further clinical exploration and promotion of this therapeutic approach in the treatment of NB.
Autres résumés
Type: plain-language-summary
(eng)
Point 1. The inadequate effectiveness of traditional chemotherapy in individuals with recurrent or resistant neuroblastoma (NB) necessitates the investigation of novel therapeutic approaches. Point 2. Arsenic trioxide (ATO)-based salvage treatments are both effective and less toxic in relapsed or refractory NB. Point 3. Salvage chemotherapy regimens incorporating ATO have shown promise in extending disease stabilization in relapsed or refractory high-risk NB patients, with favorable efficacy and safety profiles, which suggests further clinical exploration and promotion of this therapeutic approach in the treatment of NB.
Identifiants
pubmed: 39266997
doi: 10.1186/s12885-024-12884-5
pii: 10.1186/s12885-024-12884-5
doi:
Substances chimiques
Arsenic Trioxide
S7V92P67HO
Topotecan
7M7YKX2N15
Cyclophosphamide
8N3DW7272P
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1140Subventions
Organisme : Guangzhou Area Clinical Specialty Technology Program
ID : 2023P-TS39
Organisme : Sun Yat-Sen Medical-Industrial Integration Cultivating Program
ID : YXYGRH202203
Organisme : Heilongjiang Harbin Yida Pharmaceutical Co.
ID : 7670020013
Informations de copyright
© 2024. The Author(s).
Références
Matthay KK, Maris JM, Schleiermacher G, Nakagawara A, Mackall CL, Diller L, Weiss WA. Neuroblastoma. Nat Rev Dis Primers. 2016;2:16078.
doi: 10.1038/nrdp.2016.78
pubmed: 27830764
Qiu B, Matthay KK. Advancing therapy for neuroblastoma. Nat Rev Clin Oncol. 2022;19(8):515–33.
doi: 10.1038/s41571-022-00643-z
pubmed: 35614230
Zeineldin M, Patel AG, Dyer MA. Neuroblastoma: when differentiation goes awry. Neuron. 2022;110(18):2916–28.
doi: 10.1016/j.neuron.2022.07.012
pubmed: 35985323
pmcid: 9509448
Monclair T, Brodeur GM, Ambros PF, Brisse HJ, Cecchetto G, Holmes K, Kaneko M, London WB, Matthay KK, Nuchtern JG, von Schweinitz D, Simon T, Cohn SL, Pearson AD, INRG Task Force. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol. 2009;27(2):298–303.
doi: 10.1200/JCO.2008.16.6876
pubmed: 19047290
pmcid: 2650389
Tan AC, Ashley DM, López GY, Malinzak M, Friedman HS, Khasraw M. Management of glioblastoma: state of the art and future directions. CA Cancer J Clin. 2020;70(4):299–312.
doi: 10.3322/caac.21613
pubmed: 32478924
Lau DT, Hesson LB, Norris MD, Marshall GM, Haber M, Ashton LJ. Prognostic significance of promoter DNA methylation in patients with childhood neuroblastoma. Clin Cancer Res. 2012;18(20):5690–700.
doi: 10.1158/1078-0432.CCR-12-0294
pubmed: 22929802
Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature. 2019;575(7782):299–309.
doi: 10.1038/s41586-019-1730-1
pubmed: 31723286
pmcid: 8008476
Zafar A, Wang W, Liu G, Wang X, Xian W, McKeon F, Foster J, Zhou J, Zhang R. Molecular targeting therapies for neuroblastoma: progress and challenges. Med Res Rev. 2021;41(2):961–1021.
doi: 10.1002/med.21750
pubmed: 33155698
Chung C, Boterberg T, Lucas J, Panoff J, Valteau-Couanet D, Hero B, Bagatell R, Hill-Kayser CE. Neuroblastoma. Pediatr Blood Cancer. 2021;68(Suppl 2):e28473.
doi: 10.1002/pbc.28473
pubmed: 33818884
Qi K, Li Y, Huang K, Xiong X, Chuchu F, Zhang C, Weng W. Pre-application of arsenic trioxide may potentiate cytotoxic effects of vinorelbine/docetaxel on neuroblastoma SK-N-SH cells. Biomed Pharmacother. 2019;113:108665.
doi: 10.1016/j.biopha.2019.108665
pubmed: 30889490
Liu L, Li Y, Xiong X, Qi K, Zhang C, Fang J, Guo H. Low dose of arsenic trioxide inhibits multidrug resistant-related P-glycoprotein expression in human neuroblastoma cell line. Int J Oncol. 2016;49(6):2319–30.
doi: 10.3892/ijo.2016.3756
pubmed: 27840903
Chen S, Wu JL, Liang Y, Tang YG, Song HX, Wu LL, Xing YF, Yan N, Li YT, Wang ZY, Xiao SJ, Lu X, Chen SJ, Lu M. Arsenic trioxide rescues structural p53 mutations through a cryptic allosteric site. Cancer Cell. 2021;39(2):225–e2398.
doi: 10.1016/j.ccell.2020.11.013
pubmed: 33357454
Li C, Peng X, Feng C, Xiong X, Li J, Liao N, Yang Z, Liu A, Wu P, Liang X, He Y, Tian X, Lin Y, Wang S, Li Y. Excellent early outcomes of combined chemotherapy with arsenic trioxide for stage 4/M neuroblastoma in children: a multicenter nonrandomized controlled trial. Oncol Res. 2021;28(7):791–800.
doi: 10.3727/096504021X16184815905096
pubmed: 33858561
pmcid: 8420893
Li Y, Feng C, Chen Y, Huang K, Li C, Xiong X, Li P, Zhou D, Peng X, Weng W, Deng X, Wu Y, Fang J. Improved outcomes with induction chemotherapy combined with arsenic trioxide in stage 4 neuroblastoma: a case series. Technol Cancer Res Treat. 2021;20:15330338211041454.
doi: 10.1177/15330338211041454
pubmed: 34569870
pmcid: 8485563
Irwin MS, Naranjo A, Zhang FF, Cohn SL, London WB, Gastier-Foster JM, Ramirez NC, Pfau R, Reshmi S, Wagner E, Nuchtern J, Asgharzadeh S, Shimada H, Maris JM, Bagatell R, Park JR, Hogarty MD. Revised neuroblastoma risk classification system: a report from the children’s oncology group. J Clin Oncol. 2021;39(29):3229–41.
doi: 10.1200/JCO.21.00278
pubmed: 34319759
pmcid: 8500606
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.
doi: 10.1016/j.ejca.2008.10.026
pubmed: 19097774
US Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) Version 4.03. Bethesda, MD: National Institutes of Health; 2010.
Basta NO, Halliday GC, Makin G, Birch J, Feltbower R, Bown N, Elliott M, Moreno L, Barone G, Pearson AD, James PW, Tweddle DA, McNally RJ. Factors associated with recurrence and survival length following relapse in patients with neuroblastoma. Br J Cancer. 2016;115(9):1048–57.
doi: 10.1038/bjc.2016.302
pubmed: 27701387
pmcid: 5117794
Herd F, Basta NO, McNally RJQ, Tweddle DA. A systematic review of re-induction chemotherapy for children with relapsed high-risk neuroblastoma. Eur J Cancer. 2019;111:50–8.
doi: 10.1016/j.ejca.2018.12.032
pubmed: 30822684
pmcid: 6458963
Zage PE. Novel therapies for relapsed and refractory neuroblastoma. Child (Basel). 2018;5(11):148.
Kushner BH, Kramer K, Modak S, Qin LX, Cheung NK. Differential impact of high-dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma. Cancer. 2010;116(12):3054–60.
doi: 10.1002/cncr.25232
pubmed: 20564411
Garaventa A, Luksch R, Biasotti S, Severi G, Pizzitola MR, Viscardi E, Prete A, Mastrangelo S, Podda M, Haupt R, De Bernardi B. A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma. Cancer. 2003;98(11):2488–94.
doi: 10.1002/cncr.11797
pubmed: 14635085
Ashraf K, Shaikh F, Gibson P, Baruchel S, Irwin MS. Treatment with topotecan plus cyclophosphamide in children with first relapse of neuroblastoma. Pediatr Blood Cancer. 2013t;60(10):1636–41.
doi: 10.1002/pbc.24587
pubmed: 23650219
Simon T, Längler A, Harnischmacher U, Frühwald MC, Jorch N, Claviez A, Berthold F, Hero B. Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma. Results of a phase-II trial. J Cancer Res Clin Oncol. 2007;133(9):653–61.
doi: 10.1007/s00432-007-0216-y
pubmed: 17479288
Kobayashi M, Mizutani A, Nishi K, Muranaka Y, Nishii R, Shikano N, Nakanishi T, Tamai I, Kleinerman ES, Kawai K. [131I]MIBG exports via MRP transporters and inhibition of the MRP transporters improves accumulation of [131I]MIBG in neuroblastoma. Nucl Med Biol. 2020;90–91:49–54.
doi: 10.1016/j.nucmedbio.2020.09.004
pubmed: 33032192
Calvet L, Santos A, Valent A, Terrier-Lacombe MJ, Opolon P, Merlin JL, Aubert G, Morizet J, Schellens JH, Bénard J, Vassal G. No topoisomerase I alteration in a neuroblastoma model with in vivo acquired resistance to irinotecan. Br J Cancer. 2004;91(6):1205–12.
doi: 10.1038/sj.bjc.6602079
pubmed: 15292932
pmcid: 2747712
Lin KS, Uemura S, Thwin KKM, Nakatani N, Ishida T, Yamamoto N, Tamura A, Saito A, Mori T, Hasegawa D, Kosaka Y, Nino N, Nagano C, Takafuji S, Iijima K, Nishimura N. Minimal residual disease in high-risk neuroblastoma shows a dynamic and disease burden-dependent correlation between bone marrow and peripheral blood. Transl Oncol. 2021;14(8):101019.
doi: 10.1016/j.tranon.2021.101019
pubmed: 33993097
pmcid: 8138775
He B, Mao J, Huang L. Clinical characteristics and survival outcomes in neuroblastoma with bone metastasis based on SEER database analysis. Front Oncol. 2021;11:677023.
doi: 10.3389/fonc.2021.677023
pubmed: 34141621
pmcid: 8203907
Campbell K, Shyr D, Bagatell R, Fischer M, Nakagawara A, Nieto AC, Brodeur GM, Matthay KK, London WB, DuBois SG. Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: a report from the International Neuroblastoma Risk Group (INRG) project. Pediatr Blood Cancer. 2019;66(8):e27819.
doi: 10.1002/pbc.27819
pubmed: 31115156
pmcid: 7323455
You H, Baluszek S, Kaminska B. Supportive roles of brain macrophages in CNS metastases and assessment of new approaches targeting their functions. Theranostics. 2020;10(7):2949–64.
doi: 10.7150/thno.40783
pubmed: 32194848
pmcid: 7053204